Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Research & Development (2016 - 2025)

Historic Research & Development for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $6.9 million.

  • Anika Therapeutics' Research & Development rose 1681.8% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.8 million, marking a year-over-year increase of 6454.28%. This contributed to the annual value of $25.5 million for FY2024, which is 1737.35% up from last year.
  • Latest data reveals that Anika Therapeutics reported Research & Development of $6.9 million as of Q3 2025, which was up 1681.8% from $6.3 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Research & Development high stood at $8.9 million for Q2 2023, and its period low was -$3.3 million during Q4 2023.
  • Its 5-year average for Research & Development is $5.9 million, with a median of $6.5 million in 2024.
  • Its Research & Development has fluctuated over the past 5 years, first plummeted by 13520.0% in 2022, then soared by 29470.38% in 2024.
  • Anika Therapeutics' Research & Development (Quarter) stood at $6.0 million in 2021, then tumbled by 135.2% to -$2.1 million in 2022, then tumbled by 58.24% to -$3.3 million in 2023, then soared by 294.7% to $6.5 million in 2024, then rose by 6.75% to $6.9 million in 2025.
  • Its Research & Development stands at $6.9 million for Q3 2025, versus $6.3 million for Q2 2025 and $6.1 million for Q1 2025.